Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AZTA
AZTA logo

AZTA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Azenta Inc (AZTA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
23.310
1 Day change
2.80%
52 Week Range
41.730
Analysis Updated At
2026/06/18
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Azenta Inc (AZTA) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has shown some positive price movement recently, the lack of significant positive catalysts, weak financial performance data availability, and neutral trading sentiment suggest that it is better to wait for more clarity or stronger signals before investing.

Technical Analysis

The MACD is positive and expanding, indicating a bullish momentum. RSI is neutral at 66.107, and moving averages are converging, suggesting no strong directional trend. Key resistance levels are at 23.588 and 24.079, while support levels are at 21.999 and 21.508. The stock has a 70% chance of a -2.32% change in the next day and a modest 0.4% gain in the next week.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The high open interest put-call ratio indicates bearish sentiment, while the low option volume put-call ratio suggests some short-term bullish activity. Implied volatility is moderate at 56.42, with an IV percentile of 59.52, indicating average volatility compared to historical levels.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
2
Buy
9

Positive Catalysts

  • Analysts maintain a Buy or Outperform rating, and the recent acquisition of UK Biocentre is expected to contribute to long-term revenue growth starting in 2027.

Neutral/Negative Catalysts

  • No recent news or significant trading trends from hedge funds, insiders, or Congress. The stock's short-term trend suggests potential minor losses in the next day.

Financial Performance

No financial data available for the latest quarter, making it difficult to assess the company's growth trends or profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have lowered price targets from $40-$45 to $35, reflecting cautious optimism. They maintain Buy or Outperform ratings, citing long-term growth potential from acquisitions.

Wall Street analysts forecast AZTA stock price to rise
6 Analyst Rating
Wall Street analysts forecast AZTA stock price to rise
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 22.675
sliders
Low
30
Averages
39.5
High
45
Current: 22.675
sliders
Low
30
Averages
39.5
High
45
Evercore ISI
Outperform
to
Outperform
downgrade
$45 -> $35
AI Analysis
2026-04-06
Reason
Evercore ISI
Price Target
$45 -> $35
AI Analysis
2026-04-06
downgrade
Outperform
to
Outperform
Reason
Evercore ISI lowered the firm's price target on Azenta to $35 from $45 and keeps an Outperform rating on the shares as part of the firm's medical technology and life science tools Q1 preview.
Jefferies
Matthew Stanton
Buy
to
Buy
downgrade
$40 -> $35
2026-04-01
Reason
Jefferies
Matthew Stanton
Price Target
$40 -> $35
2026-04-01
downgrade
Buy
to
Buy
Reason
Jefferies analyst Matthew Stanton lowered the firm's price target on Azenta to $35 from $40 and keeps a Buy rating on the shares. The firm is updating its model for the recent acquisition of UK Biocentre, noting that the deal is expected to be dilutive to adjusted EBITDA pro-forma for fiscal year in 2026 and accretive to 2027/28 organic revenue growth and adjusted EBITDA margin.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for AZTA
Unlock Now

People Also Watch